X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (10) 10
index medicus (10) 10
transplantation (9) 9
female (8) 8
adult (7) 7
hematology (7) 7
hematology, oncology and palliative medicine (7) 7
male (7) 7
middle aged (7) 7
stem cells (7) 7
aged (6) 6
article (6) 6
immunology (6) 6
antineoplastic agents - therapeutic use (5) 5
hematopoietic stem cells (4) 4
bone marrow (3) 3
cancer (3) 3
chemotherapy (3) 3
multiple myeloma (3) 3
oncology (3) 3
patient outcomes (3) 3
surgical procedures, operative (3) 3
transplantation, autologous (3) 3
adolescent (2) 2
antibodies, monoclonal - therapeutic use (2) 2
bone marrow transplantation - adverse effects (2) 2
bone-marrow (2) 2
boronic acids - therapeutic use (2) 2
bortezomib (2) 2
care and treatment (2) 2
dexamethasone (2) 2
disease (2) 2
drug therapy (2) 2
follow-up studies (2) 2
graft vs host disease - mortality (2) 2
gvhd (2) 2
hematopoietic stem cell transplantation - adverse effects (2) 2
hematopoietic stem cell transplantation - methods (2) 2
hodgkin disease - therapy (2) 2
immunotherapy (2) 2
lymphoma (2) 2
lymphomas (2) 2
medical colleges (2) 2
multiple myeloma - drug therapy (2) 2
multiple myeloma - therapy (2) 2
peripheral blood stem cell transplantation (2) 2
pyrazines - therapeutic use (2) 2
stem cell transplantation (2) 2
thalidomide (2) 2
therapy (2) 2
transplantation, homologous (2) 2
transplants & implants (2) 2
versus-host-disease (2) 2
abridged index medicus (1) 1
acetylglucosamine (1) 1
acute disease (1) 1
acute graft-versus-host disease (1) 1
acute gvhd (1) 1
acute myeloid-leukemia (1) 1
african americans (1) 1
aged, 80 and over (1) 1
allogeneic (1) 1
allogeneic hematopoietic stem cell transplantation (1) 1
amphotericin b (1) 1
analysis (1) 1
angiogenesis inhibitors (1) 1
antibacterial agents (1) 1
antibodies (1) 1
antibodies, monoclonal, murine-derived (1) 1
antibody formation (1) 1
antifungal (1) 1
antifungal agents (1) 1
antifungal agents - administration & dosage (1) 1
antifungal agents - therapeutic use (1) 1
antifungal agents [administration & dosage] (1) 1
antigens (1) 1
antimitotic agents (1) 1
antineoplastic agents (1) 1
antineoplastic agents, alkylating - therapeutic use (1) 1
applied microbiology and biotechnology (1) 1
aspergillosis (1) 1
aspergillosis - drug therapy (1) 1
aspergillosis [drug therapy] (1) 1
autografts (1) 1
autologous stem cell transplantation (1) 1
bacterial infections and mycoses (1) 1
blood and marrow transplant (1) 1
blood and marrow transplant clinical trials network (1) 1
blood cell count - drug effects (1) 1
blood component removal (1) 1
bmt ctn 0902 (1) 1
bone marrow transplant (1) 1
bone marrow transplantation (1) 1
bone marrow transplantation - education (1) 1
bone marrow transplantation - methods (1) 1
bone marrow transplantation - trends (1) 1
bone-marrow transplantation (1) 1
bortezomib maintenance (1) 1
calcineurin inhibitors - therapeutic use (1) 1
cancer therapies (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 9, pp. 1283 - 1294
Journal Article
Cancer, ISSN 0008-543X, 02/1978, Volume 41, Issue 2, pp. 701 - 705
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2015, Volume 21, Issue 1, pp. 55 - 59
Abstract We sought to determine whether differences in chronic graft-versus-host disease (GVHD) rates would lead to survival differences by comparing 2463... 
Hematology, Oncology and Palliative Medicine | Chronic graft-versus-host disease | Mortality | Leukemia | STEM-CELLS | disease | Chronic graft-versus-host | RANDOMIZED-TRIAL | FOLLOW-UP | IMMUNOLOGY | VERSUS-HOST-DISEASE | CHRONIC GRAFT | TRANSPLANTATION | PROPHYLAXIS | GLOBULIN | MOBILIZED BLOOD | HEMATOLOGY | Graft vs Host Disease - therapy | Myeloablative Agonists - therapeutic use | Leukemia, Biphenotypic, Acute - therapy | Humans | Middle Aged | Male | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy | Graft vs Host Disease - immunology | Transplantation, Homologous | Myelodysplastic Syndromes - therapy | Graft vs Host Disease - mortality | Time Factors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Bone Marrow Transplantation | Adult | Female | Unrelated Donors | Leukemia, Biphenotypic, Acute - mortality | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - immunology | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Leukemia, Biphenotypic, Acute - pathology | Leukemia, Biphenotypic, Acute - immunology | Graft vs Host Disease - pathology | Calcineurin Inhibitors - therapeutic use | Adolescent | Myelodysplastic Syndromes - mortality | Survival Analysis | Aged | Transplantation Conditioning | Myelodysplastic Syndromes - pathology | Chronic Disease | Peripheral Blood Stem Cell Transplantation | Myelodysplastic Syndromes - immunology | Medical colleges | Bone marrow | Organ transplant recipients | Transplantation | Hematopoietic stem cells | Index Medicus
Journal Article
Journal Article
British Journal of Haematology, ISSN 0007-1048, 06/2009, Volume 145, Issue 6, pp. 816 - 824
Summary Prior therapy with rituximab might attenuate disparate histocompatibility antigen presentation by B cells, thus decreased the risk of acute... 
allogeneic | rituximab | graft-versus-host disease | lymphoma | transplantation | Allogeneic | Graft-versus-host disease | Rituximab | Transplantation | Lymphoma | MONOCLONAL-ANTIBODY TREATMENT | COMPARING METHOTREXATE | FOLLICULAR LYMPHOMA | IDIOPATHIC THROMBOCYTOPENIC PURPURA | IN-VIVO | NON-HODGKINS-LYMPHOMA | DEPLETING THERAPY | LOW-GRADE | MARROW-TRANSPLANTATION | HEMATOLOGY | CYCLOSPORINE | Follow-Up Studies | Humans | Lymphoma, B-Cell - therapy | Middle Aged | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Case-Control Studies | Transplantation Conditioning - mortality | Transplantation, Homologous | Incidence | Young Adult | Graft vs Host Disease - mortality | Adult | Female | Transplantation Conditioning - methods | Lymphoma, B-Cell - drug therapy | Antibodies, Monoclonal, Murine-Derived | Lymphoma, B-Cell - mortality | Proportional Hazards Models | Treatment Outcome | Combined Modality Therapy | Disease-Free Survival | Graft vs Host Disease - prevention & control | Aged | Peripheral Blood Stem Cell Transplantation | Medical colleges | Care and treatment | Patient outcomes | HLA histocompatibility antigens | Development and progression | Antineoplastic agents | Hematopoietic stem cells | Antimitotic agents | Histocompatibility antigens | Stem cells | Bone marrow | Lymphomas | Cancer | Index Medicus | GVHD
Journal Article
Supportive Care in Cancer, ISSN 0941-4355, 9/2013, Volume 21, Issue 9, pp. 2437 - 2442
Journal Article
Transplant Research and Risk Management, ISSN 1179-1616, 2011, Volume 3, pp. 31 - 44
Acute graft-versus-host disease (aGVHD) is an immunologically mediated inflammatory reaction, which continues to be a major cause of morbidity and mortality in... 
Acute graft-versus-host disease | Acute GVHD | Bone marrow transplant | GVHD | Disease prevention | Antigens
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2003, Volume 9, Issue 3, pp. 189 - 197
Reduced conditioning intensity has extended the option of allogeneic hematopoietic stem cell transplantation to patients who cannot tolerate fully... 
Reduced-intensity regimen | Allogeneic hematopoietic stem cell transplantation
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2016, Volume 22, Issue 10, pp. 1747 - 1757
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.